{"id":2136,"date":"2017-05-23T18:06:22","date_gmt":"2017-05-23T12:36:22","guid":{"rendered":"https:\/\/www.delveinsight.com\/blog\/?p=2136"},"modified":"2021-07-24T12:56:46","modified_gmt":"2021-07-24T07:26:46","slug":"notizia-40","status":"publish","type":"post","link":"https:\/\/www.delveinsight.com\/blog\/notizia-40","title":{"rendered":"AZ\u2019s benralizumab; Sanofi, Regeneron set; Nordisk preps; European countries offer"},"content":{"rendered":"<div id=\"ez-toc-container\" class=\"ez-toc-v2_0_76 counter-hierarchy ez-toc-counter ez-toc-white ez-toc-container-direction\">\n<p class=\"ez-toc-title\" style=\"cursor:inherit\">Table of Contents<\/p>\n<label for=\"ez-toc-cssicon-toggle-item-6a03c20dc702b\" class=\"ez-toc-cssicon-toggle-label\"><span class=\"\"><span class=\"eztoc-hide\" style=\"display:none;\">Toggle<\/span><span class=\"ez-toc-icon-toggle-span\"><svg style=\"fill: #999;color:#999\" xmlns=\"http:\/\/www.w3.org\/2000\/svg\" class=\"list-377408\" width=\"20px\" height=\"20px\" viewBox=\"0 0 24 24\" fill=\"none\"><path d=\"M6 6H4v2h2V6zm14 0H8v2h12V6zM4 11h2v2H4v-2zm16 0H8v2h12v-2zM4 16h2v2H4v-2zm16 0H8v2h12v-2z\" fill=\"currentColor\"><\/path><\/svg><svg style=\"fill: #999;color:#999\" class=\"arrow-unsorted-368013\" xmlns=\"http:\/\/www.w3.org\/2000\/svg\" width=\"10px\" height=\"10px\" viewBox=\"0 0 24 24\" version=\"1.2\" baseProfile=\"tiny\"><path d=\"M18.2 9.3l-6.2-6.3-6.2 6.3c-.2.2-.3.4-.3.7s.1.5.3.7c.2.2.4.3.7.3h11c.3 0 .5-.1.7-.3.2-.2.3-.5.3-.7s-.1-.5-.3-.7zM5.8 14.7l6.2 6.3 6.2-6.3c.2-.2.3-.5.3-.7s-.1-.5-.3-.7c-.2-.2-.4-.3-.7-.3h-11c-.3 0-.5.1-.7.3-.2.2-.3.5-.3.7s.1.5.3.7z\"\/><\/svg><\/span><\/span><\/label><input type=\"checkbox\"  id=\"ez-toc-cssicon-toggle-item-6a03c20dc702b\"  aria-label=\"Toggle\" \/><nav><ul class='ez-toc-list ez-toc-list-level-1 ' ><li class='ez-toc-page-1 ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-1\" href=\"https:\/\/www.delveinsight.com\/blog\/notizia-40\/#AstraZenecas_new_benralizumab_helps_severe_asthma_patients_cut_back_on_steroids\" >AstraZeneca&#8217;s new benralizumab helps severe asthma patients cut back on steroids<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-2\" href=\"https:\/\/www.delveinsight.com\/blog\/notizia-40\/#Sanofi_Regeneron_set_Kevzara_up_for_tough_RA_turf_battle_with_39K_list_price\" >Sanofi, Regeneron set Kevzara up for tough RA turf battle with $39K list price<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-3\" href=\"https:\/\/www.delveinsight.com\/blog\/notizia-40\/#Novo_Nordisk_preps_Saxenda_sales_drive_in_Latin_America_after_its_%E2%80%98phenomenal_Q1\" >Novo Nordisk preps Saxenda sales drive in Latin America after its &#8216;phenomenal&#8217; Q1<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-4\" href=\"https:\/\/www.delveinsight.com\/blog\/notizia-40\/#European_countries_offer_goodies_in_bid_to_win_EMA_after_Brexit\" >European countries offer goodies in bid to win EMA after Brexit<\/a><\/li><\/ul><\/nav><\/div>\n<h3 style=\"text-align: justify;\"><span class=\"ez-toc-section\" id=\"AstraZenecas_new_benralizumab_helps_severe_asthma_patients_cut_back_on_steroids\"><\/span>AstraZeneca&#8217;s new benralizumab helps severe asthma patients cut back on steroids<span class=\"ez-toc-section-end\"><\/span><\/h3>\n<p style=\"text-align: justify;\">AstraZeneca&#8217;s respiratory candidate benralizumab can help some severe asthma patients cut down on\u2014or even stop\u2014the unsavory steroid pills they use daily to stave off attacks, a new study showed. Dubbed Zonda, the phase 3 trial found that patients taking benralizumab were more than four times more likely to reduce oral steroid use than those who received a placebo. And 52% of eligible patients were able to completely discontinue the pills, investigators reported, while still seeing reductions in asthma exacerbations. In addition to cutting back on steroids, patients on benralizumab saw a 70% reduction in the rate of exacerbations compared to those on placebo. The respiratory biologic was associated with a 93% reduction in exacerbations that required emergency room visits. AZ unveiled the new data at the American Thoracic Society conference in Washington, D.C. The findings were simultaneously published in the New England Journal of Medicine. Benralizumab has an FDA action date during the fourth quarter of 2017. Until then, AZ is preparing to be ready in the beginning of next year to launch this product.<\/p>\n<h3 style=\"text-align: justify;\"><span class=\"ez-toc-section\" id=\"Sanofi_Regeneron_set_Kevzara_up_for_tough_RA_turf_battle_with_39K_list_price\"><\/span>Sanofi, Regeneron set Kevzara up for tough RA turf battle with $39K list price<span class=\"ez-toc-section-end\"><\/span><\/h3>\n<p style=\"text-align: justify;\">Sanofi and Regeneron just added another building block to a nascent immunology franchise expected to bring in $5 billion or more by 2022. But to get there, their new Kevzara will have to go up against a host of other rheumatoid arthritis meds already on the market\u2014and a few still on their way. One way Kevzara can do that? A lower price, according to doctors surveyed by GlobalData analysts. And Kevzara will have a list price of $39,000 per year, the companies say, 30% lower than the two most widely used TNF-alpha drugs, which will be among its chief competitors. Kevzara&#8217;s nod comes more than six months after the FDA turned back the drug on manufacturing problems at a Sanofi plant where drugs are filled and finished. The two companies worked with the agency to fix them, and after a successful inspection earlier this year, the Kevzara approval was widely expected. Kevzara (sarilumab) is Sanofi and Regeneron\u2019s second entry into the immunology field, after the approval of Dupixent, a treatment for severe eczema, in March.<\/p>\n<h3 style=\"text-align: justify;\"><span class=\"ez-toc-section\" id=\"Novo_Nordisk_preps_Saxenda_sales_drive_in_Latin_America_after_its_%E2%80%98phenomenal_Q1\"><\/span>Novo Nordisk preps Saxenda sales drive in Latin America after its &#8216;phenomenal&#8217; Q1<span class=\"ez-toc-section-end\"><\/span><\/h3>\n<p style=\"text-align: justify;\">Novo Nordisk, facing more pressure than ever in the U.S., is revving up for a push into Latin America with its obesity drug Saxenda, hoping to put already-promising sales into a higher gear. The drug maker plans to expand its capacity in Latin America and step up its efforts in the obesity market there. The Danish drugmaker sees a particular opportunity in Mexico. Saxenda generated sales of $81 million for the first quarter, including $10.5 million in Latin America. Novo first launched Saxenda in 2015 in an effort to diversify beyond diabetes, a business that has had trouble growing lately due to competitive pressures in the U.S. The Danish drugmaker rolled its obesity shot out at $1,000 per month and said it has \u201cblockbuster potential.\u201d In Latin America, Doustdar said he believes Novo can expand the entire obesity market as well as capture a share of it with Saxenda.<\/p>\n<h3 style=\"text-align: justify;\"><span class=\"ez-toc-section\" id=\"European_countries_offer_goodies_in_bid_to_win_EMA_after_Brexit\"><\/span>European countries offer goodies in bid to win EMA after Brexit<span class=\"ez-toc-section-end\"><\/span><\/h3>\n<p style=\"text-align: justify;\">Even before European officials present the groundwork for relocating the bloc\u2019s drug regulator, a fight has emerged between countries vying for the economic lift and status that come with hosting the authority, using perks like child care as ammo. Some 20 countries in Europe hope to host the European Medicines Agency after the U.K.\u2019s vote to leave the union last summer. And even though the EU hasn\u2019t announced its official criteria for the move, the countries aren\u2019t hesitating to make their case by showcasing local lifestyle perks and more. Countries in Europe are offering language lessons, local scenery and child care as they push to win the EMA, according to the news service. They\u2019re seeking to attract an agency that could bring an economic lift worth an estimated \u20ac1 billion and employs about 900 experts.<\/p>\n","protected":false},"excerpt":{"rendered":"<p>AstraZeneca&#8217;s new benralizumab helps severe asthma patients cut back on steroids AstraZeneca&#8217;s respiratory candidate benralizumab can help some severe asthma patients cut down on\u2014or even stop\u2014the unsavory steroid pills they use daily to stave off attacks, a new study showed. Dubbed Zonda, the phase 3 trial found that patients taking benralizumab were more than four [&hellip;]<\/p>\n","protected":false},"author":1,"featured_media":1712,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"_acf_changed":false,"_editorskit_title_hidden":false,"_editorskit_reading_time":0,"_editorskit_is_block_options_detached":false,"_editorskit_block_options_position":"{}","advgb_blocks_editor_width":"","advgb_blocks_columns_visual_guide":"","footnotes":""},"categories":[32],"tags":[1875,96,17315,786,709,877,639,504,2019,533],"industry":[17225],"therapeutic_areas":[17227,17243],"class_list":["post-2136","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-notizia","tag-asthma","tag-astrazeneca","tag-benralizumab","tag-brexit","tag-ema","tag-novo-nordisk","tag-pharma-news","tag-regeneron","tag-rheumatoid-arthritis","tag-sanofi","industry-pharmaceutical","therapeutic_areas-immunological-and-autoimmune-disorders","therapeutic_areas-respiratory-diseases"],"acf":[],"yoast_head":"<!-- This site is optimized with the Yoast SEO Premium plugin v25.8 (Yoast SEO v25.8) - https:\/\/yoast.com\/wordpress\/plugins\/seo\/ -->\n<title>AZ\u2019s benralizumab; Sanofi, Regeneron set; Nordisk preps<\/title>\n<meta name=\"description\" content=\"AstraZeneca&#039;s respiratory candidate benralizumab can help some severe asthma patients cut down on\u2014or even stop\u2014the unsavory...\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.delveinsight.com\/blog\/notizia-40\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"AZ\u2019s benralizumab; Sanofi, Regeneron set; Nordisk preps\" \/>\n<meta property=\"og:description\" content=\"AstraZeneca&#039;s respiratory candidate benralizumab can help some severe asthma patients cut down on\u2014or even stop\u2014the unsavory...\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.delveinsight.com\/blog\/notizia-40\" \/>\n<meta property=\"og:site_name\" content=\"DelveInsight Business Research\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/DelveInsight-1423323754607782\/\" \/>\n<meta property=\"article:published_time\" content=\"2017-05-23T12:36:22+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2021-07-24T07:26:46+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2016\/12\/09021232\/news.jpg\" \/>\n\t<meta property=\"og:image:width\" content=\"960\" \/>\n\t<meta property=\"og:image:height\" content=\"343\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/jpeg\" \/>\n<meta name=\"author\" content=\"DelveInsight\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:creator\" content=\"@DelveInsight\" \/>\n<meta name=\"twitter:site\" content=\"@DelveInsight\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"DelveInsight\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"3 minutes\" \/>\n<!-- \/ Yoast SEO Premium plugin. -->","yoast_head_json":{"title":"AZ\u2019s benralizumab; Sanofi, Regeneron set; Nordisk preps","description":"AstraZeneca's respiratory candidate benralizumab can help some severe asthma patients cut down on\u2014or even stop\u2014the unsavory...","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.delveinsight.com\/blog\/notizia-40","og_locale":"en_US","og_type":"article","og_title":"AZ\u2019s benralizumab; Sanofi, Regeneron set; Nordisk preps","og_description":"AstraZeneca's respiratory candidate benralizumab can help some severe asthma patients cut down on\u2014or even stop\u2014the unsavory...","og_url":"https:\/\/www.delveinsight.com\/blog\/notizia-40","og_site_name":"DelveInsight Business Research","article_publisher":"https:\/\/www.facebook.com\/DelveInsight-1423323754607782\/","article_published_time":"2017-05-23T12:36:22+00:00","article_modified_time":"2021-07-24T07:26:46+00:00","og_image":[{"width":960,"height":343,"url":"https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2016\/12\/09021232\/news.jpg","type":"image\/jpeg"}],"author":"DelveInsight","twitter_card":"summary_large_image","twitter_creator":"@DelveInsight","twitter_site":"@DelveInsight","twitter_misc":{"Written by":"DelveInsight","Est. reading time":"3 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"WebPage","@id":"https:\/\/www.delveinsight.com\/blog\/notizia-40","url":"https:\/\/www.delveinsight.com\/blog\/notizia-40","name":"AZ\u2019s benralizumab; Sanofi, Regeneron set; Nordisk preps","isPartOf":{"@id":"https:\/\/www.delveinsight.com\/blog\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.delveinsight.com\/blog\/notizia-40#primaryimage"},"image":{"@id":"https:\/\/www.delveinsight.com\/blog\/notizia-40#primaryimage"},"thumbnailUrl":"https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2016\/12\/09021232\/news.jpg","datePublished":"2017-05-23T12:36:22+00:00","dateModified":"2021-07-24T07:26:46+00:00","author":{"@id":"https:\/\/www.delveinsight.com\/blog\/#\/schema\/person\/5fbf6ca478835d03fdb5e17d905b520a"},"description":"AstraZeneca's respiratory candidate benralizumab can help some severe asthma patients cut down on\u2014or even stop\u2014the unsavory...","inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.delveinsight.com\/blog\/notizia-40"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.delveinsight.com\/blog\/notizia-40#primaryimage","url":"https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2016\/12\/09021232\/news.jpg","contentUrl":"https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2016\/12\/09021232\/news.jpg","width":960,"height":343},{"@type":"WebSite","@id":"https:\/\/www.delveinsight.com\/blog\/#website","url":"https:\/\/www.delveinsight.com\/blog\/","name":"DelveInsight Business Research","description":"Blog","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.delveinsight.com\/blog\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/www.delveinsight.com\/blog\/#\/schema\/person\/5fbf6ca478835d03fdb5e17d905b520a","name":"DelveInsight","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.delveinsight.com\/blog\/#\/schema\/person\/image\/","url":"https:\/\/secure.gravatar.com\/avatar\/afdd550c64e18f6ad8957080b017c6ae55f4916951d641d3cd40264176aa0e86?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/afdd550c64e18f6ad8957080b017c6ae55f4916951d641d3cd40264176aa0e86?s=96&d=mm&r=g","caption":"DelveInsight"}}]}},"author_meta":{"display_name":"DelveInsight","author_link":"https:\/\/www.delveinsight.com\/blog\/author\/gtadmin"},"featured_img":"https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2016\/12\/09021232\/news-300x107.jpg","coauthors":[],"tax_additional":{"categories":{"linked":["<a href=\"https:\/\/www.delveinsight.com\/blog\/notizia\/\" class=\"advgb-post-tax-term\">Notizia - Recent Pharma, Healthcare and Biotech Happenings<\/a>"],"unlinked":["<span class=\"advgb-post-tax-term\">Notizia - Recent Pharma, Healthcare and Biotech Happenings<\/span>"]},"tags":{"linked":["<a href=\"https:\/\/www.delveinsight.com\/blog\/notizia\/\" class=\"advgb-post-tax-term\">asthma<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/notizia\/\" class=\"advgb-post-tax-term\">AstraZeneca<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/notizia\/\" class=\"advgb-post-tax-term\">Benralizumab<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/notizia\/\" class=\"advgb-post-tax-term\">Brexit<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/notizia\/\" class=\"advgb-post-tax-term\">EMA<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/notizia\/\" class=\"advgb-post-tax-term\">Novo Nordisk<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/notizia\/\" class=\"advgb-post-tax-term\">pharma news<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/notizia\/\" class=\"advgb-post-tax-term\">Regeneron<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/notizia\/\" class=\"advgb-post-tax-term\">rheumatoid arthritis<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/notizia\/\" class=\"advgb-post-tax-term\">Sanofi<\/a>"],"unlinked":["<span class=\"advgb-post-tax-term\">asthma<\/span>","<span class=\"advgb-post-tax-term\">AstraZeneca<\/span>","<span class=\"advgb-post-tax-term\">Benralizumab<\/span>","<span class=\"advgb-post-tax-term\">Brexit<\/span>","<span class=\"advgb-post-tax-term\">EMA<\/span>","<span class=\"advgb-post-tax-term\">Novo Nordisk<\/span>","<span class=\"advgb-post-tax-term\">pharma news<\/span>","<span class=\"advgb-post-tax-term\">Regeneron<\/span>","<span class=\"advgb-post-tax-term\">rheumatoid arthritis<\/span>","<span class=\"advgb-post-tax-term\">Sanofi<\/span>"]}},"comment_count":"0","relative_dates":{"created":"Posted 9 years ago","modified":"Updated 5 years ago"},"absolute_dates":{"created":"Posted on May 23, 2017","modified":"Updated on Jul 24, 2021"},"absolute_dates_time":{"created":"Posted on May 23, 2017 6:06 pm","modified":"Updated on Jul 24, 2021 12:56 pm"},"featured_img_caption":"","series_order":"","_links":{"self":[{"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/posts\/2136","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/comments?post=2136"}],"version-history":[{"count":0,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/posts\/2136\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/media\/1712"}],"wp:attachment":[{"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/media?parent=2136"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/categories?post=2136"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/tags?post=2136"},{"taxonomy":"industry","embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/industry?post=2136"},{"taxonomy":"therapeutic_areas","embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/therapeutic_areas?post=2136"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}